Objective-To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) trial evaluated the effects of fenofibric acid (FA) treatment on cIMT in patients with mixed dyslipidemia on atorvastatin. Approach and Results-This multicenter, double-blind, placebo-controlled study was performed in patients with mixed dyslipidemia (fasting triglycerides, ≥150 mg/dL; high-density lipoprotein cholesterol, ≤45 [men] or 55 mg/dL [women]; low-density lipoprotein cholesterol, ≤100 mg/dL once and averaging ≤105 mg/dL) and a history of coronary heart disease or risk equivalent. Patients on background atorvastatin (continued on starting dose or titrated to 40 mg, if needed)
D espite the widespread use of statin therapy, a considerable residual risk of cardiovascular events remains. 1 Although statins reduce the relative risk of cardiovascular events by ≈20% to 50%, depending on the degree of low-density lipoprotein cholesterol (LDL-C) reduction, there remains considerable risk of future events in some subgroups of patients. 2, 3 One of the strongest predictors of residual risk is hypertriglyceridemia associated with low levels of high-density lipoprotein cholesterol (HDL-C). 1, 4, 5 In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial, patients with diabetes mellitus on simvastatin monotherapy in the upper tertile of triglycerides (≥204 mg/dL) and the lower tertile of HDL-C (≤34 mg/dL) had a cardiovascular event frequency of 17.3% compared with 10.1% in all other patients receiving simvastatin monotherapy. 4 This subgroup of patients with high triglycerides and low HDL-C represented ≈17% of the study population receiving statin monotherapy, but accounted for 25% of the cardiovascular events. The high triglycerides and low HDL-C subgroup in the ACCORD Lipid trial had not only a greater cardiovascular event rate but also a 29% relative risk reduction on fenofibrate combination therapy with simvastatin, compared with simvastatin monotherapy (12.4% versus 17.3% events; P=0.032). However, the patients outside of this dyslipidemic subgroup did not benefit from the addition of fenofibrate to simvastatin therapy (10.1% versus 10.1% events; P=0.06 for the treatment-by-subgroup interaction). These results are consistent with those from the 5 other cardiovascular outcome trials that evaluated the benefits of a triglyceride-lowering therapy in the subgroup of patients with significant hypertriglyceridemia. [6] [7] [8] [9] [10] The measurement of carotid intima-media thickness (cIMT) is a well-validated surrogate end point for evaluating the impact of a therapy on cardiovascular risk. 11, 12 cIMT has been shown to correlate with risk of future cardiovascular events, 11, 12 and changes in cIMT over time have been used extensively to evaluate the potential clinical efficacy of antiatherosclerotic agents. 11, 13 Statins, which are well-established agents for reducing the risk of cardiovascular disease events, have been shown to reduce the progression of cIMT. However, some controversy over the validity of cIMT as a predictor of cardiovascular event risk does exist. [13] [14] [15] [16] Furthermore, in a previous cIMT trial with fenofibrate, as a subset of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, there were no significant improvements in cIMT progression in 170 patients with diabetes mellitus. 17 The design of this trial was criticized for the relatively small sample size and for not selecting the subgroup of patients with hypertriglyceridemia that are most likely to be treated with a fibrate, and who ultimately seemed to experience improved clinical outcomes in the main FIELD study.
In patients with mixed dyslipidemia, treatment with both fenofibric acid (FA), the active metabolite of fenofibrate, and a statin has been shown to produce significantly greater improvements in HDL-C, triglycerides, and non-HDL-C than statin monotherapy and significantly greater improvements in LDL-C than FA monotherapy. 18 Therefore, the combination of FA with a statin may provide a reduction in cardiovascular events that cannot be achieved by either agent as monotherapy in a high-risk patient population with elevated triglycerides. The FIRST (Evaluation of Choline Fenofibrate (ABT-335) on cIMT in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy) trial is the first controlled prospective study to evaluate the effects of treatment with FA on cIMT progression in patients with hypertriglyceridemia and low HDL-C, whereas LDL-C was controlled on statin therapy (Figure 1 ).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Patient Characteristics
A total of 682 patients were randomized to the FA 135 mg plus atorvastatin (n=340) or placebo plus atorvastatin (n=342) groups, and 465 patients completed the study. The efficacy and safety analysis populations included 572 and 676 patients, respectively. Reasons for discontinuations are displayed in Figure 2 . Baseline demographic and clinical characteristics were comparable between treatment groups, with the exception of significantly lower mean baseline posterior-wall (0.760 versus 0.782 mm, respectively; P=0.010) and anterior-wall (0.748 versus 0.768 mm, respectively; P=0.028) cIMT values with FA plus atorvastatin therapy versus atorvastatin monotherapy (Table 1 ). In both treatment groups, a majority of patients were white and most were men: ≥77% had a history of hypertension, 50% had type 2 diabetes mellitus, 22% had a history of coronary artery disease (CAD), 11% had a history of angina, 11% had previous myocardial infarction, and >60% had prior statin use. At baseline in this trial of patients with mixed dyslipidemia, mean HDL-C was 39.8 (SD, 7.6) mg/dL, median triglycerides were 199.0 (range, 41.0-972) mg/dL, mean LDL-C was 84.3 (SD, 20.9) mg/dL, and mean non-HDL-C was 118.0 (SD, 24.9) mg/dL. The concomitant medications most commonly taken in the FA plus atorvastatin and atorvastatin monotherapy groups were acetylsalicylic acid (56.4% and 58.4%, respectively), metformin (38.0% and 37.5%, respectively), ibuprofen (25.5% and 25.4%, respectively), and lisinopril (26.1% and 24.8%, respectively). Only 2.1% and 2.7% of subjects in the FA plus atorvastatin and atorvastatin monotherapy groups, respectively, required the addition of ezetimibe to atorvastatin to maintain LDL-C within the target range.
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Efficacy End Points
The primary end point, the between-group difference in the rate of change from baseline of the mean posterior-wall cIMT of the common carotid arteries, was −0.006 mm/y (FA plus atorvastatin group, −0.006 mm/y; atorvastatin monotherapy group, 0.000 mm/y), but did not reach statistical significance (P=0.22). The absolute changes in mean posterior-wall cIMT using the last observation carried forward imputation method, conducted as a sensitivity analysis, demonstrated that both treatment groups showed a decrease in posterior-wall cIMT at week 104 compared with baseline; however, the betweengroup difference in the change from baseline was not statistically significant ( Figure 3 ). The results of 2 other sensitivity analyses were consistent with the primary analysis. In subgroup analyses of the primary efficacy end point (rate of Clinical characteristic, n (%)
Angina 28 (8) 43 (13) Cardiac arrhythmia 35 (10) 32 (9) Carotid artery disease 21 (6) 23 (7) Coronary artery disease 63 (19) 88 ( change in the posterior-wall intima-media thickness of the common carotid artery), the treatment-by-subgroup interaction was significant (interaction P<0.05) for subgroups based on age, medical history of CAD, baseline triglycerides by tertile, baseline cIMT by tertile, and baseline statin use. The treatment effect was larger (ie, favored the FA plus atorvastatin combination group) among subjects ≥60 years of age at baseline, those with a history of CAD (compared with no history of CAD), those with prior statin use (defined as any statin use in the 30-day period before the prescreening visit), those in the highest tertile of baseline cIMT, and those in the middle tertile of baseline triglycerides (Figure 4 and Figure in the online-only Data Supplement). Secondary cIMT end points were not statistically different between treatment groups in the overall study population ( Table 2 ). The significance of between-treatment group differences varied among the lipid parameters. Starting at the first postbaseline assessment and continuing through week 104, FA plus atorvastatin therapy resulted in significant improvements, compared with atorvastatin monotherapy, in HDL-C (week 104 mean change, +8.3% versus +3.6%), triglycerides (week 104 median change, −31.3% versus -2.3%, respectively), and non-HDL-C (week 104 mean change, −3.3% versus +4.9%; Figure 5 ). FA plus atorvastatin therapy resulted in LDL-C values that were significantly higher versus atorvastatin monotherapy through week 52, but no significant difference was observed subsequently through week 104 (89.2 versus 90.6 mg/dL, respectively; Figure 5 ). Most other parameters were well controlled on atorvastatin monotherapy at baseline (Table 3 ). Between-group differences in percentage changes were generally more favorable with FA plus atorvastatin therapy versus atorvastatin monotherapy, reaching statistical significance (nominal P values that were not adjusted for multiple comparisons) for total cholesterol (week 104), very low-density lipoprotein cholesterol (VLDL; weeks 52 and 104), apolipoprotein AII (weeks 52 and 104), apolipoprotein B 100 (week 104), apolipoprotein CIII associated with particles containing apolipoprotein B (weeks 52 and 104), and high-sensitivity C-reactive protein (week 52), but not apolipoprotein AI (Table 3) . FA plus atorvastatin therapy resulted in a significant increase in LDL particle number and size relative to monotherapy (mean particle number at week 104: 1212 versus 1126 nmol/L for FA plus atorvastatin versus atorvastatin monotherapy; particle size at week 104: 20.3 versus 20.1 nm, respectively); statistically significant changes also were seen for HDL and VLDL particle numbers and sizes (Table 3 ).
Safety
The frequencies of adverse events overall were comparable between treatment groups ( Table 4 ). The frequency of adverse events leading to discontinuation was significantly higher in patients treated with FA plus atorvastatin therapy versus atorvastatin monotherapy (13.9% versus 6.5%, respectively; P=0.001; Figure 2 ; Table 4 ). Based on adjudicated events, there were no significant differences between the FA plus atorvastatin therapy and atorvastatin monotherapy groups for composites of cardiovascular events ( Table 4 ). The event rate for the first occurrence of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke was low in both treatment groups (1.8% in each group). The event rate for the first occurrence of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina, and hospitalization for heart failure also was similar in the 2 treatment groups (FA plus atorvastatin group, 4.1%; atorvastatin monotherapy, 4.7%). The frequency of adverse events of special interest was significantly higher overall with combination therapy (8.9%) than with monotherapy (2.7%; P<0.001; Table 4 ). The majority of events of special interest were kidney related. Specifically, the acute renal failure Standardized MedDRA Query, a broadly inclusive search strategy focused on identifying events related to renal impairment, was 6.5% in the combination therapy group and 0.9% *Because the primary end point did not demonstrate a statistically significant difference between treatment groups, the ranked secondary end points were to be tested within the context of the prespecified multiple testing plan.
in the monotherapy group. Two patients in the combination therapy group and none in the monotherapy group had creatinine levels ≥3.0 (women) or ≥3.5 (men) mg/dL. No patients with renal failure required dialysis or kidney transplantation. Chemistry findings of special interest were mostly comparable between treatment groups; however, compared with the monotherapy group, more patients in the combination therapy group experienced a ≥50% increase from baseline in creatinine (P≤0.001); an estimated glomerular filtration rate <45 mL/min, corrected for body surface area (P≤0.001); and a ≥50% decrease from baseline in estimated glomerular filtration rate (P=0.02; Table 4 ).
Discussion
FA in combination with atorvastatin significantly lowered triglycerides and increased HDL-C concentrations but did not significantly improve cIMT progression compared with atorvastatin monotherapy. Although the primary end point was not achieved in this surrogate end point trial, there are several important issues with regard to the effects in prespecified subgroups that may provide insights into the potential benefits of combination therapy to address residual cardiovascular risk with statin monotherapy. In patients with pre-existing CAD, older age, thicker baseline cIMT, or higher levels of triglycerides, there seemed to be a significant reduction in cIMT progression with combination therapy compared with statin monotherapy. Patients in these subgroups also had the greatest progression of cIMT on statin therapy, which supports the concept that, in patients with enhanced cardiovascular risk, atherosclerosis progression continues despite well-controlled LDL-C on statin therapy. Treatment with fibrates in patients with hypertriglyceridemia may reduce the risk of atherosclerosis progression, although this hypothesis will require prospective verification.
Although the FIRST trial was designed to select a patient population most likely to benefit from FA therapy, the potential benefit on progression of cIMT in these prespecified subgroups suggests that a more stringent high-risk classification may be necessary to demonstrate a clinical value for combination treatment compared with statin monotherapy. Although the overall results for the FIRST population were neutral, the data from the prespecified subgroups generate the hypotheses that patients with even greater baseline levels of triglycerides (>175 mg/dL) and higher cardiovascular risk (pre-existing CAD) may benefit from FA therapy in combination with a statin.
There was an imbalance in the baseline cIMT between the 2 treatment groups. Despite the large sample size and double-blind randomization, the atorvastatin monotherapy group had a significantly higher mean baseline cIMT value compared with the FA plus atorvastatin combination treatment group. This baseline imbalance may have confounded the evaluation of the influence of combination therapy on cIMT progression. The subgroup of patients with a history of previous statin use, compared with those not taking a statin at entry, seemed to have a substantially worse cardiovascular risk factor profile. Patients with a history of statin use typically had a more advanced age and a greater prevalence of CAD (including prior myocardial infarction), hypertension, and diabetes mellitus. FA in combination with atorvastatin, while providing a profound reduction in triglycerides (≈30%), only reduced non-HDL-C modestly and increased LDL-C and LDL particle concentrations. FA is also known to increase homocysteine and creatinine, although data on a detrimental effect on homocysteine are weak. 20 There remains the possibility that there are unfavorable metabolic effects associated with fibrate therapy that may result in a less than expected clinical benefit, despite significant triglyceride reduction.
FA in combination with atorvastatin did not result in a greater risk of muscle-related or hepatic enzyme elevation-related adverse effects. However, similar to previous observations of elevated plasma creatinine with fenofibrate, 21 there were more adverse effects related to renal function in the patients in the FA plus atorvastatin treatment group compared with the monotherapy group. There is evidence from other fenofibrate trials that suggest that, once therapy is stopped, creatinine returns to baseline, 22 and long term, there seems to be a reduction in proteinuria. 4 Aggressive hydration after discontinuing treatment may facilitate resolution of renal abnormalities. 23 In conclusion, the FIRST trial failed to demonstrate decreased cIMT progression with FA plus atorvastatin compared with statin monotherapy in a higher risk patient population with hypertriglyceridemia (≥150 mg/dL). The trial produced hypothesis-generating data, which suggest that a threshold triglyceride level of ≥175 mg/dL may be required to achieve a clinical benefit with FA plus a statin. The potential benefit in patients with greater triglyceride levels supports the rationale for future studies with fibrates or other triglyceridelowering agents in statin-treated patients. Adding a fibrate to statin therapy has been hypothesized to reduce residual cardiovascular risk associated with persistently elevated triglycerides and low high-density lipoprotein cholesterol. The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy trial evaluated the effects of fenofibric acid treatment on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy. The carotid intima-media thickness measurement is a well-validated surrogate end point for evaluating the impact of a therapy on cardiovascular risk. Fenofibric acid in combination with atorvastatin significantly lowered triglycerides and increased high-density lipoprotein cholesterol concentrations but did not significantly improve carotid intima-media thickness progression compared with atorvastatin monotherapy. However, the trial produced hypothesis-generating data, which suggest that a threshold triglyceride level of ≥175 mg/dL may be required to achieve a clinical benefit with fenofibric acid plus a statin.
Significance
